107 results
8-K
EX-99.2
VANI
Vivani Medical Inc
13 May 24
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
4:57pm
under development; conduct any pre-clinical activities of our other products; our products may not demonstrate safety or efficacy in clinical trials; we … concerns) 2019–Intarcia re-submitted ITCA 650 NDA 2020–FDA issued second ITCA 650 CRL (cited clinical safety and device constituent concerns) 2022–After
8-K
EX-99.2
VANI
Vivani Medical Inc
26 Mar 24
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
8:31am
pre - clinical activities of our other products; our products may not demonstrate safety or efficacy in clinical trials; we may fail to secure … CRL (cited clinical safety and device constituent concerns) 2022 – After dispute resolutions, FDA’s CDER proposes to deny Intarcia’s public hearing
8-K
EX-99.1
sf1m ave9sh5e1gv0m
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
8-K
EX-10.1
c4s6ngfxt5g
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
8-K
EX-99.1
mqje66re7z3y86k4
28 Feb 24
Regulation FD Disclosure
8:30am
8-K
EX-99.2
lkdco9
28 Feb 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
ui5m7 15zyzz11d8x6
14 Nov 23
Results of Operations and Financial Condition
6:06am
8-K
EX-99.2
9ofrnf2wx wt50k7kt7
14 Nov 23
Results of Operations and Financial Condition
6:06am
8-K
EX-99.1
f5fehi97hekhb6
18 Sep 23
Regulation FD Disclosure
6:20am
8-K
EX-99.1
awpfs37h2kmmznhg
28 Aug 23
Entry into a Material Definitive Agreement
5:43pm
8-K
EX-3.2
86n9ymxgzah9
10 Jul 23
Material Modifications to Rights of Security Holders
4:04pm
8-K
EX-99.1
g4o1l09gkvaa
15 May 23
Results of Operations and Financial Condition
6:49am
8-K
EX-99.2
dc36tzi286atweg
15 May 23
Results of Operations and Financial Condition
6:49am
DEFR14A
iqb a8isodq0q2rr128
1 May 23
Revised proxy
4:49pm